Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InsuletBSP:P2OD34 62 EV-to-FCF is 2.62 as of Aug. 09, 2026. GuruFocus rates BSP:P2OD34 with a GF Score™ of 62/100 and a GF Value™ of R$66.65 (Significantly Undervalued). Among 412 Medical Devices & Instruments companies, Insulet ranks worse than 67.23% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Insulet's Enterprise Value is R$3,675 Mil.
Insulet's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was R$1,404 Mil. Therefore, Insulet's EV-to-FCF for today is 2.62.
The historical rank and industry rank for Insulet's EV-to-FCF or its related term are showing as below:
BSP:P2OD34'
s EV-to-FCF Range Over the Past 10 Years
Min: -1199.91 Med: -97.36 Max: 491.15
Current: 38.42
During the past 13 years, the highest EV-to-FCF of Insulet was 491.15. The lowest was -1199.91. And the median was -97.36.
BSP:P2OD34's EV-to-FCF is ranked worse than 67.23% of 412
companies
in the Medical Devices & Instruments industry
Industry Median: 24.52
vs BSP:P2OD34: 38.42
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Insulet's share price for today is R$22.68.
Insulet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$28.324.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Insulet EV-to-FCF Related Terms
Insulet EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Insulet's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:P2OD34 vs GMED, PEN, BRKR: EV-to-FCF Comparison
For the Medical Devices subindustry, Insulet's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Insulet's EV-to-FCF falls into.
Insulet's current Enterprise Value is R$3,675 Mil.
Insulet's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,404 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet (BSP:P2OD34) has a EV-to-FCF of 2.62 as of Aug. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Insulet and its competitors. According to the industry distribution chart, Insulet ranks #277 out of 412 companies in the Medical Devices & Instruments industry, placing it in the top 67.2%.
Is Insulet's EV-to-FCF too high?
Insulet's current EV-to-FCF is 2.62. The Medical Devices & Instruments industry median EV-to-FCF is 24.52. Insulet's value of 2.62 is 89.3% below this industry median. Based on the distribution chart, Insulet ranks #277 out of 412 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Insulet has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's EV-to-FCF compare to GMED and PEN?
According to the Medical Devices & Instruments industry distribution chart, Insulet ranks #277 out of 412 companies for EV-to-FCF. This places Insulet in the lower half of its industry. The industry median EV-to-FCF is 24.52. Insulet's value of 2.62 is 89.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.52, based on 412 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insulet's current EV-to-FCF of 2.62 is 89.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Insulet and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insulet's current EV-to-FCF is 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (BSP:P2OD34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$66.65, compared to a current price of R$22.68 — trading 66% below its estimated fair value. The current EV-to-FCF is 2.62 and 89.3% below the Medical Devices & Instruments industry median of 24.52. Insulet's overall GF Score™ is 62/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Insulet (BSP:P2OD34), the current EV-to-FCF is 2.62 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insulet (BSP:P2OD34) Overvalued in 2026?
Based on GuruFocus' analysis, Insulet stock appears to be undervalued.
The current stock price of R$22.68 is trading 66% below its estimated GF Value™ of R$66.65.
GuruFocus considers Insulet to be Significantly Undervalued.
Key valuation signals for BSP:P2OD34:
EV-to-FCF: 2.62
GF Value™: R$66.65 vs. price of R$22.68 (66% below fair value)
Industry Position: 89.3% below the Medical Devices & Instruments median (#277 of 412)
No single metric tells the full story. See the BSP:P2OD34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
62GF Score
Get the complete analysis for BSP:P2OD34
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:P2OD34 has been successfully added to your 
